Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DML0GIU)

• Drug Name: AIV001 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Basal cell carcinoma	2C32	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DML0GIU

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor receptor (VEGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[3]
Fruquintinib	DMHOSCQ	Colorectal cancer	2B91.Z	Approved	[4]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[4]
KH-902	DM8VO16	Diabetic macular edema	9B71.02	Phase 3	[5]
ABP 938	DM00ACQ	Neovascular age-related macular degeneration	9B78.3Z	Phase 3	[6]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
BAY-57-9352	DMVA5NS	Gastric adenocarcinoma	2B72	Phase 2	[8]
X-82	DMW1NKO	Age-related macular degeneration	9B75.0	Phase 2	[4]
Vorolanib	DMIM1U9	Non-small-cell lung cancer	2C25	Phase 2	[9]
BFH-772	DMVUX1C	Psoriasis vulgaris	EA90	Phase 2	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vascular endothelial growth factor receptor (VEGFR)	TTVJ1D8	NOUNIPROTAC	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04470726) Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of AiViva BioPharma.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53.
• [6] Clinical pipeline report, company report or official report of Amgen
• [7] National Cancer Institute Drug Dictionary (drug id 452042).
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
• [10] CA patent application no. 841416, Method of selecting therapeutic indications.